Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis

The amyloid deposits that cause disease in systemic amyloidosis always contain the normal plasma protein, serum amyloid P (SAP) component. SAP is the target of a novel immunotherapy approach now being developed to eliminate amyloid deposits. The treatment is enabled by, and critically depends on, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahota, T, Berges, A, Barton, S, Cookson, L, Zamuner, S, Richards, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360666/
https://www.ncbi.nlm.nih.gov/pubmed/26225229
http://dx.doi.org/10.1002/psp4.15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360666/
https://www.ncbi.nlm.nih.gov/pubmed/26225229
http://dx.doi.org/10.1002/psp4.15

Ejemplares similares